Abstract:
Tysabri/Natalizumab is a highly effective disease modifying therapy for
the treatment of relapsing forms of multiple sclerosis. Despite
evidence to support its use as first-line therapy, risk of
NTZ-associated progressive multifocal leukoencephalopathy (PML) has
largely contributed to it being relegated to a second-line position. Health professionals only
